Impact of KRAS and BRAF Gene Mutations on Targeted Therapies in Colorectal Cancer

被引：6

作者：

Bass, Adam ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 19期

关键词：

CETUXIMAB; RAS;

D O I：

10.1200/JCO.2011.36.1816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

[No abstract available]

引用

页码：2728 / 2729

页数：2

共 12 条

[1]

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[2]

Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[3]

MAP kinase signalling pathways in cancer [J].

Dhillon, A. S. ;

Hagan, S. ;

Rath, O. ;

Kolch, W. .

ONCOGENE, 2007, 26 (22) :3279-3290

[4]

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[5]

Ellis LM, 2006, SEMIN ONCOL, V33, pS1, DOI 10.1053/j.seminoncol.2006.08.002

[6]

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J].

Engelman, Jeffrey A. ;

Chen, Liang ;

Tan, Xiaohong ;

Crosby, Katherine ;

Guimaraes, Alexander R. ;

Upadhyay, Rabi ;

Maira, Michel ;

McNamara, Kate ;

Perera, Samanthi A. ;

Song, Youngchul ;

Chirieac, Lucian R. ;

Kaur, Ramneet ;

Lightbown, Angela ;

Simendinger, Jessica ;

Li, Timothy ;

Padera, Robert F. ;

Garcia-Echeverria, Carlos ;

Weissleder, Ralph ;

Mahmood, Umar ;

Cantley, Lewis C. ;

Wong, Kwok-Kin .

NATURE MEDICINE, 2008, 14 (12) :1351-1356

[7]

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

[8]

K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[9]

Kopetz S., 2010, J. Clin. Oncol, V28, p15s

[10]

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer [J].

Price, Timothy J. ;

Hardingham, Jennifer E. ;

Lee, Chee K. ;

Weickhardt, Andrew ;

Townsend, Amanda R. ;

Wrin, Joseph W. ;

Chua, Ann ;

Shivasami, Aravind ;

Cummins, Michelle M. ;

Murone, Carmel ;

Tebbutt, Niall C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) :2675-2682

← 1 2 →